List view / Grid view
Strategic agreement for Anti-PD-1 Antibody, BMS-936558/ONO-4538, and ORENCIA® (abatacept)...
20 September 2011 | By Bristol-Myers Squibb
Strategic agreement for Anti-PD-1 Antibody, BMS-936558/ONO-4538, and ORENCIA® (abatacept)...
The Bristol-Myers Squibb Foundation awarded five grants totaling $1.5 million...
24 June 2011 | By Bristol-Myers Squibb
The Bristol-Myers Squibb Foundation awarded five grants totaling $1.5 million...
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food…
16 June 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.
